FOSTEMSAVIR TROMETHAMINE - Generic Drug Details

What are the generic drug sources for fostemsavir tromethamine and what is the scope of patent protection?

Fostemsavir tromethamine is the generic ingredient in one branded drug marketed by Viiv Hlthcare and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fostemsavir tromethamine has thirty-nine patent family members in thirty countries.

One supplier is listed for this compound.

Summary for FOSTEMSAVIR TROMETHAMINE

International Patents:	39
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	35
What excipients (inactive ingredients) are in FOSTEMSAVIR TROMETHAMINE?	FOSTEMSAVIR TROMETHAMINE excipients list
DailyMed Link:	FOSTEMSAVIR TROMETHAMINE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FOSTEMSAVIR TROMETHAMINE

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for FOSTEMSAVIR TROMETHAMINE

J05AX	Other antivirals
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for FOSTEMSAVIR TROMETHAMINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	RUKOBIA	fostemsavir tromethamine	TABLET, EXTENDED RELEASE;ORAL	212950-001	Jul 2, 2020		RX	Yes	Yes				Y
Viiv Hlthcare	RUKOBIA	fostemsavir tromethamine	TABLET, EXTENDED RELEASE;ORAL	212950-001	Jul 2, 2020		RX	Yes	Yes			Y

Expired US Patents for FOSTEMSAVIR TROMETHAMINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	RUKOBIA	fostemsavir tromethamine	TABLET, EXTENDED RELEASE;ORAL	212950-001	Jul 2, 2020

International Patents for FOSTEMSAVIR TROMETHAMINE

Country	Patent Number	Title	Estimated Expiration
Taiwan	200600096	Prodrugs of piperazine and substituted piperidine antiviral agents
Spain	2299022
World Intellectual Property Organization (WIPO)	2005090367
Portugal	1725569

Market Dynamics and Financial Trajectory for Fostemsavir Tromethamine

Last updated: February 16, 2026

Fostemsavir tromethamine is an HIV attachment inhibitor approved by the U.S. Food and Drug Administration (FDA) in July 2020 under the brand name Rukobia. It targets resistant HIV strains by blocking viral entry into immune cells. Its market trajectory hinges on its clinical positioning, patent life, competition, manufacturing capacity, and reimbursement landscape.

Market Overview and Clinical Positioning

Fostemsavir primarily treats heavily treatment-experienced patients with multidrug-resistant HIV. Its approval fills a niche in salvage therapy, addressing unmet needs for patients failing traditional antiretroviral regimens [1]. The drug's position as a last-resort option limits its market volume but sustains high margins per unit due to specialized use.

Market Size and Adoption Trends

The global HIV therapeutics market was valued at approximately $28 billion in 2022 with an expected compound annual growth rate (CAGR) of 3% from 2023 to 2030 [2]. Fostemsavir’s contribution remains modest, accounting for less than 1% of total HIV sales, but its niche role supports steady adoption in treatment-experienced cohorts.

Adoption depends on:

• Clinician familiarity and guidelines: Integration into treatment algorithms influences prescriptions.
• Patient access programs: Insurance coverage and affordability impact real-world utilization.
• Manufacturing capacity: Sufficient supply chain infrastructure ensures consistent availability.

Pricing and Reimbursement Strategy

Fostemsavir’s list price is approximately $4,000 per month for a typical treatment regimen, corresponding to annual revenue of about $48,000 per patient [3]. The high cost reflects its specialized status and limited patient pool. Payer negotiations and prior authorization requirements function as gatekeepers, influencing revenue realization.

Patent and Market Exclusivity

The patent protecting Fostemsavir extends until 2038, with no significant generic entrants anticipated before that date [4]. Data exclusivity lasts five years post-approval, ending in 2025, delaying biosimilar or generic competition during this window.

Competitive Landscape

Fostemsavir competes with other HIV agents, notably:

• Ibalizumab (Trogarzo): Approved in 2018, administered intravenously, targeting a different HIV entry mechanism.
• Cabotegravir (ViiV Healthcare): Injectable integrase inhibitor, pending approval for long-acting formulations.
• Traditional antiretrovirals: Nucleoside reverse transcriptase inhibitors (NRTIs) and integrase inhibitors, which dominate the HIV treatment paradigm.

Fostemsavir’s differentiation lies in use for multidrug-resistant, heavily treatment-experienced populations where other options have failed.

Regulatory and Clinical Development

The drug continues post-approval studies exploring broader HIV populations and potential combination regimens. These studies could extend its market reach and influence future reimbursement frameworks.

Financial Outlook

Revenue projections are constrained by:

• Small patient population (estimated 1.2% of all HIV patients are heavily treatment-experienced and multidrug resistant).
• Limited pipeline expansion for Fostemsavir itself.
• Competition influencing market share.

Assuming adoption stabilizes at 3,000 to 5,000 patients globally, annual revenues could reach $150 million to $240 million in the next five years, depending on market penetration and pricing negotiations [5].

Key Market Risks

• Patent cliffs approaching in 2038.
• Competition from newer long-acting formulations.
• Payer restrictions limiting access.
• Clinical trials yielding broader approved indications.

Summary

Fostemsavir tromethamine sustains a niche but critical role in resistant HIV treatment. Market growth depends on clinician adoption, reimbursement policies, and competitive developments. Revenue streams are expected to be steady but capped due to limited patient population and high treatment costs.

---

Key Takeaways

• Fostemsavir targets heavily treatment-experienced, multidrug-resistant HIV patients, representing a small but steady revenue source.
• Its patent protection extends to 2038, supporting revenue stability in the medium term.
• The drug faces competition from other HIV agents, notably injectable long-acting therapies.
• Price and reimbursement negotiations significantly influence final market uptake.
• Market growth potential remains limited without pipeline expansion or broader indications.

FAQs

1. What is the primary clinical niche for Fostemsavir?
   It treats heavily treatment-experienced patients with multidrug-resistant HIV when other options have failed.

2. When does patent protection for Fostemsavir expire?
   Patents extend until 2038, delaying generic competition.

3. What factors limit the revenue potential for Fostemsavir?
   Small patient population, high treatment cost, competition from other therapies, and payer restrictions.

4. How does Fostemsavir's pricing compare to other HIV drugs?
   At approximately $4,000 per month, it is priced higher than most standard regimens but comparable to other salvage therapies.

5. What is the outlook for Fostemsavir’s market share?
   Expected to remain modest, supporting revenues between $150 million and $240 million annually in the next five years.

---

References

1. FDA approved label: Fostemsavir (Rukobia). U.S. Food and Drug Administration. 2020.
2. Grand View Research. HIV Therapeutics Market Size, Trends, and Forecasts (2023-2030).
3. Manufacturer’s pricing information, 2023.
4. Patent analysis report, 2022.
5. Market analyst projections, 2023.